Discover an SMA treatment that’s delivered directly to the central nervous system to
target an underlying cause of motor neuron loss in SMA3,8,9

How does SPINRAZA work?

SPINRAZA is a modified antisense oligonucleotide designed to target an underlying cause of motor neuron loss in SMA3

Explore the MOA
Data and Safety Profile

SPINRAZA has more than 8 years of clinical trial follow-up10

Safety Profile
Dedicated Patient Support

If patients or caregivers are experiencing nonmedical barriers to accessing treatment–such as the cost of SPINRAZA–Biogen may be able to help

View Support

Extensive real-world experience across a broad range of ages1,10

have been treated with
SPINRAZA worldwide11†

there’s someone from almost every
age group who has taken
SPINRAZA3,12

have been treated with
SPINRAZA worldwide11†‡

†Based on commercial patients, early access patients, and clinical trial participants through May 2022.11
‡Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose and did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.3

a later-onset SMA who is being treated with SPINRAZA

“Around age 32, I had moved across the country and started working with a new doctor. I was feeling weaker but learning to accept it. My doctor mentioned a treatment to me called SPINRAZA.” —Ian

INDICATION

SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides. Patients may be at increased risk of bleeding complications.

In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 24 of 146 SPINRAZA-treated patients (16%) with high, normal, or unknown platelet count at baseline developed a platelet level below the lower limit of normal, compared to 10 of 72 sham-controlled patients (14%). Two SPINRAZA-treated patients developed platelet counts <50,000 cells per microliter, with the lowest level of 10,000 cells per microliter recorded on study day 28.

Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. SPINRAZA is present in and excreted by the kidney. In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 71 of 123 SPINRAZA-treated patients (58%) had elevated urine protein, compared to 22 of 65 sham-controlled patients (34%).

Laboratory testing and monitoring to assess safety should be conducted. Perform a platelet count, coagulation laboratory testing, and quantitative spot urine protein testing at baseline and prior to each dose of SPINRAZA and as clinically needed.

Severe hyponatremia was reported in an infant treated with SPINRAZA requiring salt supplementation for 14 months.

Cases of rash were reported in patients treated with SPINRAZA.

SPINRAZA may cause a reduction in growth as measured by height when administered to infants, as suggested by observations from the controlled study. It is unknown whether any effect of SPINRAZA on growth would be reversible with cessation of treatment.

The most common adverse reactions (≥20% of SPINRAZA-treated patients and ≥5% more frequently than in control patients) that occurred in the infantile-onset controlled study were lower respiratory infection and constipation. Serious adverse reactions of atelectasis were more frequent in SPINRAZA-treated patients (18%) than in control patients (10%). Because patients in this controlled study were infants, adverse reactions that are verbally reported could not be assessed. The most common adverse reactions that occurred in the later-onset controlled study were pyrexia, headache, vomiting, and back pain. Post-lumbar puncture syndrome has also been observed after the administration of SPINRAZA.

Please see full Prescribing Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

References

1. Coratti G, Cutrona C, Pera MC, et al. Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis. 2021;161(1):430. 2. De Vivo DC, Bertini E, Swoboda KJ, et al; NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842-856. 3. SPINRAZA. Prescribing Information. Biogen; 2023. 4. Finkel RS, Mercuri E, Darras BT, et al; ENDEAR Study Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Eng J Med. 2017;377(18):1723-1732. 5. Mercuri E, Darras BT, Chiriboga CA, et al; CHERISH Study Group. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Eng J Med. 2018;378(7):625-635. 6. Hagenacker T, Wurster CD, Günther R. Appendix to: Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317-325. 7. Crawford TO, Kirschner J, Ryan MM, et al; NURTURE Study Group. Nusinersen effect in infants in the presymptomatic stage of SMA: 4.9-year interim of the NURTURE study. Presented at: Muscular Dystrophy Association (MDA) 4th Clinical and Scientific Conference. March 13–16, 2022; Nashville, TN. 8. Food and Drug Association, Center for Drug Evaluation and Research. Nusinersen clinical pharmacology and biopharmaceutics review(s). White Oak, MD; 2016. 9. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371:2120-2133. 10. Biogen Data on File [as of 9/21]. 11. Biogen Data on File [as of 5/22]. 12. Biogen Data on File [as of 6/20].

Stay Connected
Sign up with us to receive the latest news, support information, and upcoming events.

ABOUT SMA
What Is SMA Multidisciplinary Care
Why SPINRAZA
About SPINRAZA How SPINRAZA Works Presymptomatic Efficacy Early-Onset Efficacy Later-Onset Efficacy Safety
Starting SPINRAZA
How to Start Find a Treatment Center Dosing & Administration
Patients on Therapy
Adults on SPINRAZA Children on SPINRAZA
Support
Access & Reimbursement SMA360°™ Patient Support

©2023 Biogen. All rights reserved.
This site is intended for US Healthcare Professionals only.
SPZ-US-3383 v9 10/23